Surgically discovered xanthogranulomatous pyelonephritis invading inferior vena cava with coexisting renal cell carcinoma.

Xanthogranulomatous pyelonephritis (XGP) is a chronic inflammatory process that results in replacement of renal and/or perirenal tissue with a diffuse infiltrate of inflammatory cells referred to as xanthoma cells. We present a case of a 49-year-old man with an incidentally discovered renal mass with inferior vena cava (IVC) thrombus, who was found intraoperatively to have a significant inflammatory process involving the posterior wall of his IVC and right renal vein consistent with XGP surrounding a focus of clear cell renal cell carcinoma in the midportion of his right kidney.

Systemic and cell-specific immune response to laparoscopic and open nephrectomy in porcine model.

PURPOSE: To determine differences in the systemic and cell-specific immune response to open and laparoscopic nephrectomy in the porcine model. MATERIALS AND METHODS: Twenty male pigs (25-40 kg) were vaccinated with human adenovirus containing ovalbumin (Ova) and 3 weeks later underwent a sham procedure (N = 4), laparoscopic nephrectomy (LN)(N = 8), or open nephrectomy (ON) (N = 8). Blood was collected after anesthesia induction and immediately and 24 and 48 hours postoperatively and assayed for complete blood count (CBC), cortisol, and C-reactive protein (CRP). Natural killer (NK) cells were isolated and stimulated in vitro for 48 hours with polyinosinic:polycytidylic acid (Poly I:C) and interleukin (IL)-2 to determine cytotoxic activity. Peripheral blood mononuclear cells (PBMC) were isolated for flow cytometry staining with CD8, CD4, and CD25 markers. Additional PBMCs were stimulated in vitro with Ova and ConA for 48 hours to measure the production of IL-10 and interferon (IFN)-gamma and a thymidine-incorporation assay to determine T-cell proliferation. RESULTS: One animal in the ON group had signs of infection preoperatively and was removed from analysis. The LN took significantly longer than ON or sham nephrectomy (P = 0.002). Blood loss and animal weight were similar in the three groups. The CRP concentration increased more in the ON than the LN and sham-treatment groups in the first 48 hours (P = 0.01). No statistical differences were seen in the elevation of white blood cells or cortisol concentration. All groups demonstrated a decrease in the cytotoxic activity of NK cells postoperatively, with a significantly greater decrease in the sham-treated animals (P = 0.004). The LN group demonstrated greater T-cell activation than the ON and sham-treatment groups with both CD4(+) (P = 0.002) and CD8(+) (P = 0.028) cells increasing their expression of the activation marker CD25. The thymidine-incorporation assay demonstrated decreased T-cell proliferation in the ON group when stimulated with ConA (P = 0.014). Production of IL-10 decreased in the sham-treated and LN animals while increasing after ON. There was no difference in IFN-gamma among the groups. CONCLUSIONS: In a porcine model, ON produces higher CRP concentrations postoperatively, a larger decrease in T-cell proliferation ability, and more IL-10 activity than LN or sham treatment. Animals undergoing LN demonstrated greater T-cell activation postoperatively. White blood cell counts, serum cortisol concentration, and production of IFN-gamma were similar among the groups. These findings suggest ON causes greater immune suppression than LN in the porcine model.

Successful outcomes of older donors in laparoscopic donor nephrectomy.

BACKGROUND AND PURPOSE: Healthy older living donors (> 50 years) are helping meet increasing demands for kidney transplantation. Live donor grafts perform better than cadaveric donor grafts; however, concern surrounds the expected nephron loss of the donors as well as the relative safety to the donor. We examined the effect age had on living laparoscopic donor and recipient outcomes at a single institution. PATIENTS AND METHODS: We retrospectively reviewed records of 101 patients who underwent laparoscopic donor nephrectomy (LDN) from October 2001 to December 2005. Twenty-nine (29%) who were aged 50 years or older, denoted as the "older" group, were compared with the remaining 72 (71%) donors who were younger than 50 years and served as controls. Perioperative and follow-up data were analyzed for both groups. RESULTS: The mean age at the time of donation was 36.1 and 54.3 years for control and older donors, respectively (P < 0.001). Baseline mean creatinine level was 0.82 mg/dL for controls and 0.84 mg/dL for older donors (P = 0.78). Complications in controls and the older group were 18% and 17%, respectively. One-year transplant survival was 100% for the controls and 96% for the older group. Average creatinine level at longer follow-up of 19 months for controls and 23 months for the older group (P = 0.34) was 1.22 mg/dL and 1.16 mg/dL, respectively (P = 0.535). CONCLUSION: LDN in donors older than 50 years of age appears safe and demonstrates similar outcomes compared with the control cohort of patients younger than 50 years. Age between 50 and 65 years should not exclude a potential donor who otherwise satisfies donor nephrectomy criteria.

Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.

OBJECTIVES: To evaluate the effect of the bacille Calmette-Guérin (BCG) failure pattern in patients with non-muscle-invasive bladder cancer on the subsequent response to intravesical immunotherapy. METHODS: Data from the national Phase II multicenter trial for BCG plus interferon-alpha intravesical therapy for non-muscle-invasive bladder cancer were analyzed. The cancer-free rates for BCG-naive (BCG-N) and BCG-failure (BCG-F) patients with different failure patterns were compared using Kaplan-Meier analysis. RESULTS: At a median follow-up of 24 months, the BCG-N and BCG-F patients had a cancer-free rate of 59% and 45%, respectively. The BCG-F patients with immediate recurrence (refractory disease), within 6, 6 to 12, 12 to 24, and longer than 24 months had a cancer-free rate of 34%, 41%, 43%, 53%, and 66%, respectively (P = 0.005 for trend). No statistically significant difference was found in the cancer-free rates between patients with failure after 12 months and those with failure after 24 months or between BCG-N patients and those with failure after 12 and 24 months. A multivariate analysis of patients with failure after 12 months revealed that the number of previous courses of BCG did not significantly affect the treatment response. CONCLUSIONS: Patients with non-muscle-invasive bladder cancer with disease recurrence more than 1 year after BCG treatment and who were treated with low-dose BCG plus interferon-alpha had response rates similar to those of BCG-N patients treated with regular-dose BCG plus interferon. Although cystectomy should still be strongly considered, these patients might benefit from another trial with intravesical immunotherapy. In contrast, recurrence within 1 year of BCG treatment should lead to consideration of either cystectomy or alternative intravesical therapies.

Hurdles to helium gas laparoscopy and a readily available alternative.

BACKGROUND AND PURPOSE: Although multiple series of helium insufflation-assisted laparoscopic surgery are reported, we encountered difficulty at many levels when arranging a laparoscopic nephrectomy with helium insufflation. We present our experience with attempting to use helium gas as an insufflant and our successful use of argon gas as an adjunct to CO(2) insufflation with a case report as illustration. MATERIALS AND METHODS: The patient is a 66-year-old man with a progressively enlarging 3.1-cm right renal mass. His history is significant for severe chronic obstructive pulmonary disease, necessitating home oxygen and frequent cycles of steroids. In line with the patient's desire for a minimally invasive procedure, we scheduled a laparoscopic nephrectomy with helium gas. Helium tanks need specialized adapters (yoke) to connect to laparoscopic insufflators; once the yoke was located, we were informed that helium is not approved by the Food and Drug Administration for use as an insufflant and we could not proceed with its use without a full hospital institutional review board review. We elected to use low-pressure CO(2) insufflation augmented by argon gas insufflation via the argon beam coagulator. RESULTS: The patient tolerated the low-pressure CO(2) /argon gas pneumoperitoneum without difficulty. There were no significant changes in the hemodynamic variables throughout the procedure. This patient was extubated at the completion of the procedure, and there were no intraoperative or postoperative complications. CONCLUSIONS: Although numerous reports and case series exist regarding the use of helium as an alternate insufflation agent to CO(2), the logistics of obtaining the correct helium yoke and hospital approval are cumbersome for this rarely indicated agent. A far simpler alternative, with similar physiologic effects, is the use of argon gas as an adjunct to CO(2) insufflation, or in lieu of CO(2) insufflation.

Objective and quality-of-life outcomes with bone-anchored male bulbourethral sling.

OBJECTIVES: To investigate the success rates and quality-of-life outcomes with the male bulbourethral sling using the validated Male Urogenital Distress Inventory (MUDI) and Male Urinary Symptom Impact Questionnaire (MUSIQ). These validated incontinence questionnaires for men have not been reported in the sling population. METHODS: A total of 31 consecutive patients underwent placement of a male bulbourethral bone-anchoring sling from October 2002 through May 2005. The preoperative information included history and physical examination, pad history, urodynamic findings, and MUDI and MUSIQ results. Postoperatively, the patients were evaluated clinically and completed a MUDI and MUSIQ every 6 months. RESULTS: Of the 31 patients, 24 completed the questionnaires and follow-up protocol. Of the other 7 patients, 4 underwent sling removal and 3 were lost to follow-up. The average follow-up time was 15 months (range 9 to 21). After surgery, the pad use decreased from a median of 3.7 pads/day (range 1 to 12) to 1.3 pads/day (range 0 to 6). Of the 24 analyzed patients, 18 (75%) were dry or using 1 pad or less per day, and 9 (38%) no longer needed pads. Subjectively, 75% of the patients were satisfied. The mean MUDI and MUSIQ scores decreased from 56.8 and 29.9 preoperatively to 44.8 (P <0.0001) and 14.6 (P = 0.002) after sling placement, respectively. When all 31 patients were included, our clinical success rate of 1 pad/day or less decreased to 58%. CONCLUSIONS: Of the 24 patients with follow-up data, 75% were satisfied and were clinically cured. A significant improvement was seen after surgery in the MUDI and MUSIQ scores, severity of incontinence, and average pad use. The MUDI and MUSIQ scores paralleled patient satisfaction and clinical success after male bulbourethral sling placement.

Bilateral testicular masses: an unusual presentation of neuroblastoma.

We describe a rare occurrence of an 11-month-old male infant with metastatic bilateral testicular neuroblastoma presenting with bilateral scrotal swelling.